Sotera Health (NASDAQ:SHC – Get Free Report) and MaxCyte (NASDAQ:MXCT – Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, profitability, earnings and risk.
Analyst Ratings
This is a summary of current ratings and price targets for Sotera Health and MaxCyte, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Sotera Health | 1 | 1 | 9 | 0 | 2.73 |
| MaxCyte | 1 | 1 | 1 | 0 | 2.00 |
Sotera Health currently has a consensus target price of $21.38, suggesting a potential upside of 18.59%. MaxCyte has a consensus target price of $5.00, suggesting a potential upside of 259.20%. Given MaxCyte’s higher probable upside, analysts clearly believe MaxCyte is more favorable than Sotera Health.
Profitability
This table compares Sotera Health and MaxCyte’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Sotera Health | 13.44% | 40.12% | 7.55% |
| MaxCyte | -114.77% | -18.92% | -16.14% |
Institutional and Insider Ownership
91.0% of Sotera Health shares are held by institutional investors. Comparatively, 68.8% of MaxCyte shares are held by institutional investors. 15.4% of Sotera Health shares are held by company insiders. Comparatively, 4.1% of MaxCyte shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Earnings and Valuation
This table compares Sotera Health and MaxCyte”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Sotera Health | $1.16 billion | 4.42 | $77.94 million | $0.57 | 31.62 |
| MaxCyte | $33.03 million | 4.35 | -$44.63 million | ($0.33) | -4.22 |
Sotera Health has higher revenue and earnings than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than Sotera Health, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Sotera Health has a beta of 1.85, suggesting that its stock price is 85% more volatile than the S&P 500. Comparatively, MaxCyte has a beta of 1.49, suggesting that its stock price is 49% more volatile than the S&P 500.
Summary
Sotera Health beats MaxCyte on 13 of the 14 factors compared between the two stocks.
About Sotera Health
Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems. The company also provides microbiological and analytical chemistry testing, as well as technical assistance, regulatory consulting, and advisory services. It serves medical devices, pharmaceuticals, food safety, agricultural products, cancer treatment, and high-performance materials industries, as well as commercial, advanced, and specialty application industries. The company was formerly known as Sotera Health Topco, Inc. and changed its name to Sotera Health Company in October 2020. Sotera Health Company was incorporated in 2015 and is headquartered in Broadview Heights, Ohio.
About MaxCyte
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
Receive News & Ratings for Sotera Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sotera Health and related companies with MarketBeat.com's FREE daily email newsletter.
